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Nayyar Iqbal1*, Artist Parker2, Robert Frederich1, Mark Donovan1 and Boaz Hirshberg2Abstract
Background: It is important to establish the cardiovascular (CV) safety profile of novel antidiabetic drugs.
Methods: Pooled analyses were performed of 20 randomized controlled studies (N = 9156) of saxagliptin as
monotherapy or add-on therapy in patients with type 2 diabetes mellitus (T2DM) as well as a subset of 11
saxagliptin + metformin studies. Adjudicated major adverse CV events (MACE; CV death, myocardial infarction [MI],
and stroke) and investigator-reported heart failure were assessed, and incidence rates (IRs; events/100 patient-years)
and IR ratios (IRRs; saxagliptin/control) were calculated (Mantel-Haenszel method).
Results: In pooled datasets, the IR point estimates for MACE and individual components of CV death, MI, and
stroke favored saxagliptin, but the 95% CI included 1. IRR (95% CI) for MACE in the 20-study pool was 0.74 (0.45,
1.25). The Cox proportional hazard ratio (95% CI) was 0.75 (0.46, 1.21), suggesting no increased risk of MACE in the
20-study pool. In the 11-study saxagliptin + metformin pool, the IRR for MACE was 0.93 (0.44, 1.99). In the 20-study
pool, the IRR for heart failure was 0.55 (0.27, 1.12).
Conclusions: Analysis of pooled data from 20 clinical trials in patients with T2DM suggests that saxagliptin is not
associated with an increased CV risk.
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mellitusIntroduction
Cardiovascular (CV) disease is the leading cause of mor-
tality and morbidity in patients with type 2 diabetes
mellitus (T2DM) [1]. In the United States, the preva-
lence of self-reported CV disease in people with T2DM
is estimated to be >30% [2], and CV events account for
almost 70% of diabetes-related deaths in individuals
aged ≥65 years [1].
Although epidemiologic studies suggest that hypergly-
cemia is associated with adverse CV events [3-5], the
effects of intensive glycemic control on CV outcomes in
interventional studies are not clear [6-8]. Moreover, in
some studies and with some antihyperglycemic drugs, a
tendency toward an increased risk for CV events has* Correspondence: nayyar.iqbal@bms.com
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stated.been reported [7,9,10]. However, follow-up of promin-
ent clinical trials in type 1 [11] and T2DM [12] suggest
that intensive glycemic control may reduce CV events
over the long term.
Because of the uncertainty surrounding glycemic control
and CV events and the association of increased CV events
with some antihyperglycemic drugs, in 2008 the US Food
and Drug Administration recommended that CV safety
be assessed as a component of the clinical development
program of new antihyperglycemic drugs [13].
Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor
approved as an adjunct to diet and exercise to improve
glycemic control in adults with T2DM [14]. DPP-4 in-
hibitors are oral antihyperglycemic agents that inhibit
the inactivation of the incretin hormones, glucagon-like
peptide-1 (GLP-1) and glucose-dependent insulinotro-
pic peptide, resulting in increased glucose-dependent
insulin secretion and suppression of glucagon secretiond. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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have protective effects on the CV system, independent
of glucose control [16]. However, DPP-4 is increased in
patients with T2DM [17,18] and elevated circulating
DPP-4 is associated with subclinical left ventricular dys-
function in these patients [18]. Therefore, it is of inter-
est to assess the CV safety of DPP-4 inhibitors.
In randomized, controlled, clinical trials, saxagliptin was
effective and well tolerated over 24 weeks in improving
glycemic control when used as monotherapy [19,20] and
as add-on therapy to metformin [21], glyburide [22], or a
thiazolidinedione [23] in patients with T2DM. The advan-
tages of DPP-4 inhibitors are their tolerability, a low rate
of hypoglycemia, and weight neutrality [24].
Results from large outcome trials of saxagliptin in pa-
tients with prior CV disease or multiple CV risk factors
(SAVOR) [25] and alogliptin in patients after acute coron-
ary syndrome (EXAMINE) have recently been published
[26] and have shown that saxagliptin and alogliptin do not
increase or decrease major adverse CV events (MACE). In
contrast to those trials in patients with T2DM and high
CV risk, the current analysis evaluated MACE and its
individual component events of CV death, myocardial
infarction (MI) and stroke, as well as heart failure, with
saxagliptin in the general population of patients with
T2DM that participated in the saxagliptin clinical devel-
opment program. The present analysis expands on a
previous assessment of the CV safety of saxagliptin [27]
and analyzes MACE in 20 phase 2 and 3 trials of saxa-
gliptin versus placebo or active comparator.
Materials and methods
Study design
This post hoc analysis (N = 9156) used pooled data from
20 randomized phase 2b and 3b controlled clinical trials
of saxagliptin. These trials were placebo-controlled or
active-comparator studies of saxagliptin (2.5, 5, or 10 mg/d
in most studies; 20, 40, or 100 mg/d in 1 phase 2b study)
as monotherapy or add-on therapy to metformin, a sulfo-
nylurea, a thiazolidinedione, or insulin ±metformin for up
to 206 weeks (including long-term extension studies) in
patients with T2DM (Table 1). Data from the SAVOR
study in patients with prior CV disease or multiple CV
risk factors were not included in this analysis. In some
studies, rescue medication (metformin, pioglitazone, or ti-
trated insulin) was given during the study if patients met
prespecified glycemic criteria. In long-term extension
studies of monotherapy, patients in the placebo arm re-
ceived blinded metformin 500 mg. Detailed methodology
and primary findings for these studies have been published
(Table 1). Patients were followed until completion of the
study or premature discontinuation from the study. The
studies were performed in accordance with the Declar-
ation of Helsinki and all patients provided writteninformed consent. The protocols were approved by a local
ethics committee.
Analyses
Adverse events (AEs) and serious AEs (SAEs) were re-
ported by study investigators using standard reporting
procedures. AEs were coded using the Medical Diction-
ary for Regulatory Activities, version 15.0 (MedDRA).
AEs occurring up to 1 day following the last treatment
day or up to the last visit day in the short-term plus
long-term period (where applicable), whichever was
later, were included. SAEs occurring up to 30 days fol-
lowing the last treatment day or up to the last visit day
in the short-term plus long-term period, whichever was
later, were included.
Major adverse CV events, defined as CV death, MI,
stroke, and cardiac ischemic events reported by investiga-
tors were systematically identified using a list of MedDRA
preferred term (PT) diagnoses. All identified potential CV
events subsequently went through treatment-blinded adju-
dication by independent reviewers at the Duke Clinical
Research Institute (DCRI; Durham, NC; 8 studies) or the
Montreal Heart Institute (MHI; Montreal, QC, Canada; 12
studies).
Briefly, for the studies retrospectively reviewed by DCRI,
cases included all deaths, MI, and stroke events as well as
all events coded by any of the 148 MedDRA PTs repre-
senting possible ischemic events. Methods for full CV
event identification have been previously published [27].
For the 12 studies prospectively adjudicated by MHI, the
sponsor identified potential cases for adjudication based
on AEs and SAEs with PTs that correlated with the follow-
ing Standardized MedDRA Queries (SMQs) groupings, as
defined by the current version of MedDRA: “ischemic
heart disease” (adjudicated for possible MI) and “cerebro-
vascular disorders” (adjudicated for possible stroke). In
addition, SAEs (only) with PTs that correlated with the
SMQs of “cardiac arrhythmias” or “cardiac failure” were
sent for adjudication to determine if the cardiac failure or
cardiac arrhythmia was precipitated by MI. Additionally,
any event that led to death was identified for adjudication
[27]. Heart failure events were not adjudicated and were
identified based on PTs from a narrow SMQ for “cardiac
failure”.
Safety was analyzed in all treated patients, including
those meeting rescue medication criteria. Analyses of
CV events were performed using the pooled 20-study
dataset and a separate pooled subset of 11 studies of
saxagliptin add-on therapy to metformin (NCT00575588,
NCT00666458, NCT00661362, NCT00121667, NCT00327015
[included saxagliptin + placebo and saxagliptin + met-
formin vs metformin + placebo], NCT00757588 [in-
cluded saxagliptin + insulin ± metformin or insulin ±
metformin], NCT00683657, NCT00885378, NCT00918138,
Table 1 Studies included in the 20-study pool




NCT00950599 Phase 2, randomized, 6-wk (high-dose cohort) or 12-wk
(main cohort) dose ranging study in treatment-naïve patients
423 7.5–8.0 SAXA 2.5, 5, 10, 20, 40,
or 100 mg/d vs PBO
Rosenstock et al,
2008 [28]
NCT00575588† Phase 3, randomized, 52 wk + 52-wk LTE 858 7.7 SAXA 5 mg/d +MET vs
glipizide 5–20 mg/d + MET
Göke et al, 2010;
2013 [29,30]
NCT00666458† Phase 3, randomized, 18 wk 801 7.7 SAXA 5 mg/d +MET vs
SITA 100 mg/d +MET
Scheen et al,
2010 [31]
NCT00698932 Phase 3, randomized, 24 wk in treatment-naïve Asian
patients. Rescue medication: metformin
568 8.1–8.2 SAXA 5 mg/d vs PBO Pan et al, 2012 [32]
NCT00661362† Phase 3, randomized, 24 wk in Asian patients 570 7.9 SAXA 5 mg/d +MET vs
PBO +MET
Yang et al, 2011 [33]
NCT00614939 Phase 3, randomized, 12 wk + 40-wk LTE in patients with
renal impairment
170 8.1–8.5 SAXA 2.5 mg/d vs PBO
(± other OADs or INS)
Nowicki et al,
2011 [34,35]
NCT00918879 Phase 3, randomized, 24 wk in treatment-naïve Indian
patients. Rescue medication: metformin
213 8.3 SAXA 5 mg/d vs PBO Prasanna Kumar
et al, 2014 [36]
NCT00121641 Phase 3, randomized, 24 wk + 42-mo LTE in treatment-naïve
patients. Rescue medication: metformin; placebo arm:
metformin 500 mg/d during LTE




NCT00295633 Phase 3, randomized, 24 wk + 52-wk LTE.
Rescue medication: metformin
565 8.2–8.4 SAXA 2.5 or 5 mg/d + TZD vs
PBO + TZD
Hollander et al, 2009;
2011 [23,38]
NCT00121667† Phase 3, randomized, 24 wk + up to 42-mo LTE.
Rescue medication: pioglitazone
743 8.0 SAXA 2.5, 5, or 10 mg/d +
MET vs PBO +MET
DeFronzo et al,
2009; Rosenstock
et al, 2013 [21,37]
NCT00316082 Phase 3, randomized, 24 wk + 52-wk LTE in treatment-naïve
patients. Rescue medication: metformin; placebo arm:
metformin 500 mg/d during LTE
365 7.8–8.0 SAXA 2.5 mg QAM ± titration




NCT00327015† Phase 3, randomized, 24 wk + 52-wk LTE in treatment-naïve
patients. Rescue medication: pioglitazone
1306 9.4–9.6 SAXA 5 or 10 mg/d + MET vs
SAXA 10 mg/d + PBO or
MET + PBO
Jadzinsky et al, 2009;
Pfützner et al,
2011 [39,40]
NCT00313313 Phase 3, randomized, 24 wk + 52-wk LTE.
Rescue medication: metformin
768 8.4–8.5 SAXA 2.5 or 5 mg/d + GLY vs
PBO + GLY uptitrated to
15 mg/d‡
Chacra et al, 2009;
2011 [22,41]
NCT00374907 Phase 3, randomized, 12 wk + 104-wk LTE in
treatment-naïve patients. Rescue medication: metformin;
placebo arm: metformin 500 mg/d during LTE
36 6.6–6.9 SAXA 5 mg/d vs PBO Henry et al,
2011 [42]
NCT00757588† Phase 3, randomized, 24 wk + 28-wk LTE.
Rescue medication: titrated insulin
455 8.6–8.7 SAXA 5 mg/d + INS ±MET vs
PBO + INS ± MET
Barnett et al,
2012 [43]




NCT00885378† Phase 3, randomized, 12 wk 160 7.9–8.0 SAXA (2.5 mg twice daily) +
MET vs PBO MET
White et al,
2014 [45]
NCT00918138† Phase 3, randomized, 4 wk 93 8.4–8.6 SAXA 5 mg/d + MET XR
1500 mg vs MET XR
uptitration to 2000 mg¶
Neutel et al,
2013 [46]
NCT01006590† Phase 3/4, randomized, 24 wk 286 7.7–7.8 SAXA 5 mg/d +MET 1500 mg




NCT00960076† Phase 3, randomized, 18 wk 282 8.3–8.4 SAXA 5 mg/d +MET XR vs




GLY = glyburide; HbA1c = glycated hemoglobin; INS = insulin; LTE = long-term extension; MET =metformin; OAD = oral antidiabetic drug; PBO = placebo;
QAM = once daily in the morning; QPM = once daily in the evening; SAXA = saxagliptin; SITA = sitagliptin; TZD = thiazolidinedione; XR = extended release.
*Number of randomized and treated patients.
†Included in the subset analysis of studies of saxagliptin as add-on therapy to metformin.
‡Main cohort only.
§Dose increase if hyperglycemia criteria were met, up to maximum indicated dose.
¶Dose increased to indicated maximum.
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Table 2 Patient demographics and clinical characteristics
in the 20-study pool
Characteristic, n (%) All SAXA Control
(n = 5701) (n = 3455)
Age, y
<65 4681 (82.1) 2766 (80.1)
≥65 1020 (17.9) 689 (19.9)
≥75 132 (2.3) 91 (2.6)
Women 2899 (50.9) 1696 (49.1)
Race
White 3707 (65.0) 2034 (58.9)
Asian 1319 (23.1) 1001 (29.0)
Black 217 (3.8) 102 (3.0)
Other 458 (8.0) 318 (9.2)
BMI, kg/m2
<30 2914 (51.1) 1888 (54.6)
≥30 2780 (48.8) 1564 (45.3)
Not reported 7 (0.1) 3 (<0.1)
Duration of T2DM, y
≤1.5 2129 (37.3) 1076 (31.1)
≤3 2817 (49.4) 1558 (45.1)
>3– < 5 776 (13.6) 523 (15.1)
≥5 2107 (37.0) 1373 (39.7)
≥10 834 (14.6) 582 (16.8)
Not reported 1 (<0.1) 1 (<0.1)
Creatinine clearance, mL/min
<30 37 (0.6) 41 (1.2)
30– < 50 90 (1.6) 68 (2.0)
50–80 973 (17.1) 658 (19.0)
>80 4598 (80.7) 2685 (77.7)
Not reported 3 (<0.1) 3 (<0.1)
BMI = body mass index; SAXA = saxagliptin; T2DM = type 2 diabetes mellitus.
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analyses of MACE were performed for saxagliptin 2.5 mg
versus control and saxagliptin 5 mg versus control in the
20-study pool. The saxagliptin 2.5-mg group included pa-
tients who received an initial dose of saxagliptin 2.5 mg
once daily, except for those enrolled in the renal impair-
ment study (NCT00614939). The saxagliptin 5-mg group
included patients who received an initial dose of saxaglip-
tin 5 mg once daily or 2.5 mg twice daily. Patients receiv-
ing doses of saxagliptin <2.5 mg/d or >5 mg/d were not
included in the analyses by dose.
For MACE and individual CV component events, the
number of patients with the event, the time up to an
event or censoring (for patients without a MACE), the
exposure-adjusted incidence rate (IR), and the incidence
rate ratio (IRR), which provides a means to account for
differences in study duration and mean follow-up time
with saxagliptin and control, were calculated. To account
for differences between studies in patients, event rates,
and randomization ratios, the IR (number of patients with
events per 100 patient-years) with 95% CI was calculated
using the Mantel-Haenszel method, stratified by study.
Exact 95% CI was calculated for the IRR, stratified by
study. In addition, adjudicated MACE were analyzed using
a Cox proportional hazards model.
Results
Patient demographics and clinical characteristics
In the 20-study pool, demographic and clinical character-
istics were similar between the saxagliptin (n = 5701) and
control (n = 3455) groups (Table 2). Most patients were
white and <65 years of age, and 45% (control) to 49% (sax-
agliptin) had a duration of T2DM of ≤3 years. In the add-
on to metformin study pool, demographic and clinical
characteristics were also similar between the saxagliptin
(n = 2981) and control (n = 2190) groups (Table 3). There
was a higher proportion of patients with duration of
T2DM of ≤1.5 years in the 20-study pool, compared with
the 11-study saxagliptin add-on to metformin pool; other-
wise, no notable differences were observed between the
pooled populations. The total follow-up time for saxaglip-
tin and control for the 20-study pool was 6051 and 2869
patient-years, respectively, with an average follow-up time
of 1.06 years/patient and 0.83 years/patient, respectively.
The proportion of patients that prematurely discontinued
from the study varied based on the length of study. The
rate of premature discontinuation was higher with saxa-
gliptin versus control in 3 studies, higher with control ver-
sus saxagliptin in 9 studies, and similar between groups in
the remaining studies.
Cardiovascular events
In the 20-study pool, exposure time to the first MACE
or censoring was 6039 patient-years in the saxagliptingroup versus 2864 patient-years in the control group. A
total of 43 patients who received saxagliptin had an ad-
judicated MACE versus 31 patients in the control group
(Figure 1). The IRs per 100 patient-years (SE) were 0.85
(0.14) for saxagliptin and 1.12 (0.20) for control, with an
IRR (95% CI) of 0.74 (0.45, 1.25). The Cox proportional
hazard ratio (HR; 95% CI) was 0.75 (0.46, 1.21), suggesting
no increased risk of MACE in the 20-study pool.
In the subgroup analyses of adjudicated MACE for
saxagliptin 2.5 and 5 mg in the 20-study pool, the IR per
100 patient-years (SE) was 0.47 (0.19) for saxagliptin
2.5 mg versus 1.38 (0.36) for control and 0.73 (0.15) for
saxagliptin 5 mg versus 0.97 (0.19) for control. The IRR
(95% CI) for saxagliptin 2.5 and 5 mg were 0.33 (0.10,
0.89) and 0.74 (0.40, 1.36), respectively (Figure 1).
In the 11-study pool of saxagliptin add-on to metformin,
the exposure time to a first MACE event or censoring was
3287 patient-years in the saxagliptin group versus 1783
Table 3 Patient demographics and clinical characteristics
in the pool of saxagliptin add-on to metformin studies
Characteristic, n (%) All SAXA Control
(n = 2981) (n = 2190)
Age, y
<65 2397 (80.4) 1733 (79.1)
≥65 584 (19.6) 457 (20.9)
≥75 86 (2.9) 62 (2.8)
Women 1533 (51.4) 1070 (48.9)
Race
White 2031 (68.1) 1426 (65.1)
Asian 549 (18.4) 469 (21.4)
Black 109 (3.7) 58 (2.6)
Other 292 (9.8) 237 (10.8)
BMI, kg/m2
<30 1438 (48.2) 1114 (50.9)
≥30 1541 (51.7) 1074 (49.0)
Not reported 2 (<0.1) 2 (<0.1)
Duration of T2DM, y
≤1.5 828 (27.8) 504 (23.0)
≤3 1198 (40.2) 833 (38.0)
>3– < 5 475 (15.9) 386 (17.6)
≥5 1308 (43.9) 971 (44.3)
≥10 489 (16.4) 391 (17.9)
Creatinine clearance, mL/min
30– < 50 28 (0.9) 14 (0.6)
50–80 493 (16.5) 405 (18.5)
>80 2457 (82.4) 1768 (80.7)
Not reported 3 (0.1) 3 (0.1)
BMI = body mass index; SAXA = saxagliptin; T2DM = type 2 diabetes mellitus.
0.1
Favors SAXA
Patients With MACE (Exposure
SAXA       Control
20-study pool      43 (6039)     31 (2864)
2.5 mg         6 (1346)    15 (1113)
        5 mg         23 (3184)     26 (2800)
Add-on to MET    23 (3287)     14 (1783)
pool
Figure 1 Incidence rate ratios for saxagliptin vs control (point estima
2.5- and 5-mg subanalysis, and the add-on to metformin study pool.
up to an event or censoring). IRR = incidence rate ratio; MACE =major adve
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who received saxagliptin had an adjudicated MACE versus
14 patients in the control group (Figure 1). The IR per 100
patient-years (SE) was similar for saxagliptin (0.79 [0.17])
and control (0.85 [0.23]), yielding an IRR (95% CI) of 0.93
(0.44, 1.99).
In the 20-study pool, the IR point estimates (SE) for
the individual components of MACE were 0.34 (0.09)
for saxagliptin versus 0.54 (0.14) for control for CV
death; 0.40 (0.10) versus 0.45 (0.13), respectively, for MI;
and 0.27 (0.07) versus 0.36 (0.11) for stroke (Figure 2).
In the 11-study pool of saxagliptin add-on to metformin,
IR estimates (SE) for saxagliptin versus control were
0.27 (0.10) versus 0.49 (0.18) for CV death, 0.44 (0.13)
versus 0.31 (0.14) for MI, and 0.21 (0.08) versus 0.22
(0.11) for stroke. IRRs for these events ranged from 0.51
to 1.49 (Figure 3).
Heart failure was not defined as a component of MACE
and was not adjudicated but was analyzed separately. For
heart failure (20-study pool only), the IR (SE) was 0.34
(0.08) and 0.62 (0.15) for saxagliptin and control, respect-
ively. IRRs for these individual events ranged between 0.55
and 0.87 (Figure 2).
Discussion
In this pooled analysis of 9156 patients with T2DM from
20 phase 2 and 3 clinical trials, treatment with saxaglip-
tin was not associated with an increased risk of CV
events and heart failure compared with placebo or active
comparator. These results expand on previous findings
on the CV safety of saxagliptin reported in a meta-
analysis of 8 phase 2 and 3 trials [27]. In that analysis, a
total of 40 MACE events in 4607 patients were reported.
The relative risk (95% CI) for saxagliptin versus com-
parator for a composite endpoint of adjudicated CV
death, MI, and stroke was 0.43 (0.23, 0.80), which sug-








tes and 95% CI) for MACE in the 20-study pool, the saxagliptin
Numbers in parentheses are total patient-years of exposure (the time
rse cardiovascular events; MET =metformin; SAXA = saxagliptin.
IRR
0.1 1 10
Favors SAXA Favors Control
Patients With an Event (Exposure)




CV death       17 (6053)     15 (2871)
Myocardial     19 (6042)     12 (2867)
infarction
Stroke            16 (6049)     10 (2869)
Heart failure          21 (6045)     18 (2862)
0.55
MACE                   43 (6039)     31 (2864)
0.74
Figure 2 Incidence rate ratios for saxagliptin vs control (point estimates and 95% CI) for CV death, myocardial infarction, stroke, and
heart failure in the 20-study pool. Numbers in parentheses are total patient-years of exposure (the time up to an event or censoring).
CV = cardiovascular; IRR = incidence rate ratio; MACE =major adverse cardiovascular events; SAXA = saxagliptin.
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cluded 9156 patients who experienced 74 MACE events.
In this larger population, which should provide a more
precise risk estimate, the relative risk (95% CI) for a
composite endpoint of adjudicated CV death, MI, and
stroke was 0.75 (0.46, 1.21), suggesting no increased risk
of MACE in this 20-study pool. Incidence rates for CV
events for saxagliptin were not different from those for
placebo or comparator in most analyses, with the excep-
tion of the lower IR for MACE in the saxagliptin 2.5-mg
group in the subanalysis of the 20-study pool. However,
it should be noted that only 7 of the 20 studies included
patients who had received the 2.5-mg saxagliptin dose.
The present findings are also consistent with previously
published meta-analyses of CV events from clinical trial
programs for other DPP-4 inhibitors, including vilda-
gliptin, sitagliptin, linagliptin, and alogliptin. In a pooled
analysis of 25 clinical trials, the relative risk (95% CI)
for cardiocerebrovascular events for vildagliptin was0.1
Favors SAXA
Patients With an Event (Expos
SAXA       Control
CV death       8 (3297)     8 (1787)
Myocardial   12 (3289)     5 (1784)
infarction
Stroke           7 (3296)      4 (1786)
Figure 3 Incidence rate ratios for saxagliptin vs control (point estima
the add-on to metformin study pool. Numbers in parentheses are total
CV = cardiovascular; IRR = incidence rate ratio; SAXA = saxagliptin.0.88 (0.37, 2.11) for 50 mg once daily and 0.84 (0.62,
1.14) for 50 mg twice daily [49]. In other meta-analyses,
the IRR or HR (95% CI) for CV-related events versus
comparators was 0.83 (0.53–1.30) for sitagliptin [50],
0.34 (0.16, 0.70) for linagliptin [51], and 0.64 (1-sided
97.5% CI, 0.0, 1.406) for alogliptin [52]. In addition, a
meta-analysis of 70 trials of DPP-4 inhibitors enrolling
41,959 patients reported a reduction in MACE (n = 495
total events of CV death, nonfatal MI, and stroke and
acute coronary syndromes and/or heart failure; odds ratio,
0.71 [95% CI, 0.59, 0.86]) [53]. Although these studies
are not directly comparable because of different CV
endpoints, study designs, adjudication procedures, pa-
tient populations and background medication, all sup-
ported the hypothesis that DPP-4 inhibitors do not
increase CV risk and may possibly have CV benefits in
patients with T2DM.
Results from the large outcome trial of saxagliptin in







tes and 95% CI) for CV death, myocardial infarction, and stroke in
patient-years of exposure (the time up to an event or censoring).
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erally consistent with those were also reported from the
alogliptin trial (EXAMINE) in patients after acute cor-
onary syndrome [26]. SAVOR demonstrated neutrality
on the composite primary endpoint of CV death, MI, or
ischemic stroke (HR, 1.00 [95% CI, 0.89, 1.12]). The
MACE results reported here in a much lower-risk popu-
lation with an event rate approximately a third of that
observed in SAVOR are consistent with SAVOR in dem-
onstrating a safe profile of saxagliptin with respect to
MACE events. The fact that SAVOR did not demon-
strate superiority compared with placebo raises at least
two alternative, though not mutually exclusive, interpre-
tations: (1) evidence suggesting benefit from meta-
analysis and preclinical evidence [16,54] was due to
chance or (2) saxagliptin and likely other DPP-4 inhibi-
tors are safe in all populations and trends to benefit
occur only in the lower-risk general population studied
in the phase 3 clinical development program. The latter
hypothesis has been previously suggested based on the
only positive interaction of subgroups in a patient level
meta-analysis of UKPDS, ACCORD, ADVANCE, and
VADT [55]. Owing to the marked difference in popula-
tion characteristics (eg, age, CV history and risk factors,
duration of diabetes, background diabetes and CV medi-
cations, proportion of patients with baseline glycated
hemoglobin <7%) and population risk (3- to 6-fold higher
event rate) between SAVOR and EXAMINE and the
meta-analyses of phase 3 programs of saxagliptin and alo-
gliptin, it is difficult to support or dismiss either interpret-
ation for the lack of benefit observed in SAVOR and
EXAMINE.
SAVOR also demonstrated neutrality on the broader
composite endpoint of CV death, MI, stroke, or hos-
pitalization for unstable angina, heart failure, or coronary
revascularization (HR, 1.02 [95% CI, 0.94, 1.11]). One
component of this broader endpoint, hospitalization for
heart failure, did have an HR with 95% CI which did not
include 1 (HR, 1.27 [95% CI, 1.07, 1.51]). As reported here,
heart failure in the 20-study pool had an HR (95% CI) of
0.55 (0.27, 1.12). Again, differences in the patient popula-
tion, background medications, and/or chance may be in-
volved in the relative inconsistency of these results.
Moreover, SAVOR was an event-driven trial in a highly
defined population (prior CV disease or multiple CV risk
factors), whereas the 20 clinical trials analyzed in this
study had defined treatment periods ranging from 4 to
206 weeks and included diverse patient populations with
T2DM (eg, patients who were treatment naïve, receiving
varying background antihyperglycemic medications, or
with renal impairment). The phase 3 data presented in this
manuscript suggest that the observation of hospitalization
for heart failure could not have been anticipated based on
the phase 3 development program. It may be that furtheranalysis of SAVOR results or the other prospective CV
outcome trials with DPP-4 inhibitors [56,57] will give fur-
ther clarity to the two issues raised here.
Certain limitations of this analysis should be recognized
and considered when interpreting the results. To handle
missing data as the result of premature discontinuation,
analysis methods assumed similar event rates had the pa-
tient completed the study. However, patients treated with
saxagliptin tended to be followed longer and had a lower
rate of discontinuation compared with those who received
control treatment. Results using this assumption should
be interpreted with caution.
Both groups received a range of background medica-
tions, including metformin, sulfonylureas, and thiazoli-
dinediones and the control group received both active
medications and placebo. In several studies, a titration
of background medication [22,41,46-48] or a titration of
double-blind saxagliptin [19,29,30,39,40] was permitted.
In addition, in the majority of studies, rescue medication
was permitted [19-23,32,36,38-43]. These factors compli-
cate interpretation of the findings.
The saxagliptin group was also heterogeneous and in-
cluded patients treated with doses higher than the ap-
proved 2.5- and 5-mg once-daily doses. Further, the
analyses of the 2.5- and the 5-mg doses used distinct study
pools because not all studies included 2.5- and 5-mg arms,
which precludes direct comparison of results for the 2
doses. It is important to recognize that the pooled patient
population in these clinical trials was highly selected,
which may have resulted in a lower event rate compared
with that observed in clinical practice. Finally, there was
relatively limited experience beyond 18 months.
Conclusion
Pooled data from 20 clinical trials involving 9156 patients
with T2DM suggest that saxagliptin is safe and not associ-
ated with an increased CV risk.
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